European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany — (BUSINESS WIRE) — Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib)…